SUTTER SANTA ROSA REGIONAL HOSPITAL
- Type
- Teaching hospital
- Where
- Santa Rosa, CA
- Medicare CCN
- 050291
- Received
- $270,032 in 44 records, 2020 ($2,500 general, $267,532 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 1 | $2,500 |
| 2020 | Research payment | 43 | $267,532 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ABBVIE INC. | 25 | $212,430 | 2020 |
| UCB SA | 12 | $39,043 | 2020 |
| MicroVention, Inc. | 3 | $9,600 | 2020 |
| Celgene Corporation | 2 | $4,375 | 2020 |
| Boston Scientific Corporation | 1 | $2,500 | 2020 |
| Partner Therapeutics, Inc. | 1 | $2,084 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 43 | $267,532 |
| Charitable Contribution | 1 | $2,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-04 | ABBVIE INC. | $4,031 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-12-04 | ABBVIE INC. | $2,990 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-11-30 | Partner Therapeutics, Inc. | $2,084 | Research payment | In-kind items and services | LEUKINE Drug, Hematology | ILeukPulm | 2020 |
| 2020-11-12 | ABBVIE INC. | $20,514 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-11-12 | UCB SA | $16,292 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU | 2020 | |
| 2020-11-05 | ABBVIE INC. | $6,511 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-10-29 | MicroVention, Inc. | $2,800 | Research payment | Cash or cash equivalent | RUPTURED ANEURYSMS TREATED WITH HYDROGEL COILS (RAGE) | 2020 | |
| 2020-10-19 | UCB SA | $4,824 | Research payment | Cash or cash equivalent | Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE | 2020 | |
| 2020-10-06 | ABBVIE INC. | $3,843 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-10-06 | ABBVIE INC. | $209 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-10-01 | UCB SA | $2,170 | Research payment | Cash or cash equivalent | Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE | 2020 | |
| 2020-09-24 | UCB SA | $1,200 | Research payment | Cash or cash equivalent | Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE | 2020 | |
| 2020-09-03 | ABBVIE INC. | $3,295 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-09-03 | ABBVIE INC. | $3,034 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-08-13 | UCB SA | $2,203 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT | 2020 | |
| 2020-08-06 | ABBVIE INC. | $888 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | P12-792 | 2020 |
| 2020-08-05 | ABBVIE INC. | $12,517 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-08-05 | ABBVIE INC. | $7,226 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-08-03 | UCB SA | $586 | Research payment | Cash or cash equivalent | Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE | 2020 | |
| 2020-07-23 | UCB SA | $540 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN | 2020 | |
| 2020-07-23 | UCB SA | $500 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN | 2020 | |
| 2020-07-07 | ABBVIE INC. | $2,263 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-07-07 | ABBVIE INC. | $1,271 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-06-17 | MicroVention, Inc. | $500 | Research payment | Cash or cash equivalent | RUPTURED ANEURYSMS TREATED WITH HYDROGEL COILS (RAGE) | 2020 | |
| 2020-06-04 | ABBVIE INC. | $22,655 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-06-04 | ABBVIE INC. | $9,029 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-06-04 | UCB SA | $4,111 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN | 2020 | |
| 2020-06-04 | UCB SA | $1,500 | Research payment | Cash or cash equivalent | Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE | 2020 | |
| 2020-06-04 | UCB SA | $1,200 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN | 2020 | |
| 2020-05-13 | ABBVIE INC. | $4,500 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-05-01 | Celgene Corporation | $1,000 | Research payment | Cash or cash equivalent | REBLOZYL Biological, Hematology | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alph | 2020 |
| 2020-04-08 | Boston Scientific Corporation | $2,500 | Charitable Contribution | In-kind items and services | General Therapies Device, General | 2020 | |
| 2020-04-03 | ABBVIE INC. | $15,811 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-04-03 | ABBVIE INC. | $10,507 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-03-05 | ABBVIE INC. | $5,543 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-03-05 | ABBVIE INC. | $4,653 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-03-04 | ABBVIE INC. | $9,000 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-03-04 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-02-17 | Celgene Corporation | $3,375 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-02-10 | UCB SA | $3,915 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT | 2020 | |
| 2020-02-05 | ABBVIE INC. | $27,990 | Research payment | Cash or cash equivalent | M18-918 | 2020 | |
| 2020-02-05 | ABBVIE INC. | $10,055 | Research payment | Cash or cash equivalent | M14-397 | 2020 | |
| 2020-01-30 | MicroVention, Inc. | $6,300 | Research payment | Cash or cash equivalent | RUPTURED ANEURYSMS TREATED WITH HYDROGEL COILS (RAGE) | 2020 | |
| 2020-01-03 | ABBVIE INC. | $22,584 | Research payment | Cash or cash equivalent | M14-397 | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.
| Measure | Place (city or town) Santa Rosa, CA | County Sonoma County, CA | State California |
|---|---|---|---|
| Population B01003 | 177,090 | 485,040 | 39,287,377 |
| Population, 2020 census P1 | 178,127 | 488,863 | 39,538,223 |
| Median age B01002 | 41.2 | 42.9 | 37.9 |
| Under 18 B01001 | 20.1% | 19.0% | 22.0% |
| 65 and over B01001 | 19.0% | 21.5% | 15.7% |
| Households B11001 | 68,321 | 190,998 | 13,548,091 |
| Foreign born B05002 | 21.2% | 16.8% | 27.0% |
| Median household income B19013 | $99,060 | $104,674 | $99,122 |
| Median family income B19113 | $120,944 | $126,900 | $113,346 |
| Per capita income B19301 | $52,066 | $56,640 | $49,513 |
| Poverty rate B17001 | 9.7% | 8.9% | 12.0% |
| Unemployment rate B23025 | 6.3% | 5.7% | 6.6% |
| Civilian labor force B23025 | 96,710 | 258,155 | 20,068,466 |
| Mean commute (minutes) B08013 | 22.9 | 25.1 | 28.7 |
| Bachelor's degree or higher B15003 | 35.1% | 38.5% | 37.1% |
| Housing units B25001 | 71,382 | 207,699 | 14,644,735 |
| Owner-occupied B25003 | 56.7% | 62.6% | 55.9% |
| Renters B25003 | 43.3% | 37.4% | 44.1% |
| Median home value B25077 | $713,900 | $815,500 | $734,700 |
| Median gross rent B25064 | $2,152 | $2,158 | $2,036 |
| White, not Hispanic B03002 | 48.7% | 57.9% | 33.8% |
| Black B03002 | 1.9% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 37.4% | 30.0% | 40.2% |
| Asian B03002 | 6.3% | 4.3% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.
Comments